Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
210 hedge funds and large institutions have $3.62B invested in Juno Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 64 increasing their positions, 55 reducing their positions, and 22 closing their positions.
168% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 22
58% more capital invested
Capital invested by funds: $2.28B → $3.62B (+$1.33B)
21% more funds holding
Funds holding: 173 → 210 (+37)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
16% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 55
11% less call options, than puts
Call options by funds: $63.4M | Put options by funds: $71.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$195M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$45.5M |
| 3 |
Jennison Associates
New York
|
+$41.9M |
| 4 |
O
OrbiMed
New York
|
+$38.4M |
| 5 |
D.E. Shaw & Co
New York
|
+$31.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Crestline Management
Fort Worth,
Texas
|
-$274M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$66.3M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$26.6M |
| 4 |
State Street
Boston,
Massachusetts
|
-$19.3M |
| 5 |
Millennium Management
New York
|
-$14.1M |
JUNO Hedge Fund Activity: Q3 2017 in Review
210 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q3 2017, worth a combined $3.62B — up 58% from $2.28B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new JUNO positions and 22 closed out — a net gain of 37 holders — while 64 added to existing stakes and 55 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $195M. The largest seller was Crestline Management, cutting an estimated $274M.
- 210 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q3 2017, up from 173 in Q2 2017.
- Funds reported $3.62B of Juno Therapeutics, Inc. stock for Q3 2017, up 58% quarter-over-quarter.
- 59 funds opened new Juno Therapeutics, Inc. positions in Q3 2017 and 22 closed out, a net change of +37 holders.
- The largest Juno Therapeutics, Inc. buyer in Q3 2017 was Capital International Investors, an estimated $195M added.
- The largest Juno Therapeutics, Inc. seller in Q3 2017 was Crestline Management, an estimated $274M sold.
Based on aggregated 13F filings for Q3 2017.